M. Akil

Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study

I. Bruce, C. Gordon, D. Isenberg, 2010, The Journal of Rheumatology.

Aberrant processing of oxidative DNA damage in systemic lupus erythematosus.

J. Lunec, M. Cooke, M. Evans, 2000, Biochemical and biophysical research communications.

Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases.

Antoni B. Chan, I. Bruce, C. Gordon, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus.

I. Bruce, C. Gordon, D. Isenberg, 2007, Arthritis and rheumatism.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

S. Tuck, B. Harrison, B. Griffiths, 2022, Rheumatology.

Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus

I. Bruce, C. Gordon, D. Isenberg, 2005 .